The first and only FDA approved
at-home tDCS treatment for depression.
Flow Treatment is an FDA-approved prescription medical device for adults with moderate to severe major depressive disorder that can be used at home
What is
Flow Treatment?
Flow Treatment is a prescription medical device intended for the treatment of moderate to severe major depressive disorder in adults 18 years and older.
It uses transcranial direct current stimulation, or tDCS, and is designed to be used at home as part of a clinician-supervised treatment plan.
Flow Treatment may be prescribed as a standalone treatment or alongside antidepressant medication, where clinically appropriate.
Clinical evidence
Behind Flow Treatment
Flow FL-100 was evaluated in a 10-week, multisite, double-blind, randomized sham-controlled clinical trial in adults with major depressive disorder. In the active treatment group, 57.5% of participants achieved remission at 10 weeks. Flow FL-100 was studied both as monotherapy and as an adjunctive treatment.
Achieved remission at 10 weeks*
In remission after 10 weeks
Clinical trial duration
Clinical trial duration
Patients prescribed Flow Treatment internationally since 2019**
Patients prescribed Flow Treatment
How to access Flow
The Flow Treatment is available by prescription only and should be used under the supervision of a licensed healthcare professional. There are two ways to start.
Speak to your current clinician
Prefer to speak with your own clinician first but don't know where to start? Download a short Discussion Guide to support your conversation
Start a virtual consult
Start the process with Flow’s telehealth clinician.
1 – Complete an online eligibility check
2 – Book a virtual consultation if eligible to continue
3 – If prescribed, Flow Treatment is shipped to your home
*Remission is defined as a score of <10 on MADRS. MADRS remission rate was a secondary endpoint of the study. The primary endpoint of the study reviewed between-group mean difference in HDRS-17 scores and was –2.3 points in favour of the active group (p=0.012).
**International use data. Not all data may be directly comparable to US use. Claims subject to medical, legal and regulatory approval.
Indication
Flow Treatment is intended for the treatment of moderate to severe major depressive disorder (MDD) in the current episode, either as monotherapy or as an adjunctive treatment, in patients 18 years and older who are not considered treatment refractory to medication.
Safety information
The side effects of Flow Treatment reported in clinical studies were generally mild and transient. The main risks of the device are skin dryness, skin irritation or redness after prolonged use, transient headache, stinging, burning, or itching sensations at the stimulation site, and skin burns (typically in cases of electrode pad reuse or use of dried-out electrode pads which is not recommended).